Verona Pharma (VRNA)
62.69
-1.82 (-2.82%)
At close: Mar 28, 2025, 3:59 PM
62.88
0.30%
After-hours: Mar 28, 2025, 06:19 PM EDT
-2.82% (1D)
| Bid | 62.4 |
| Market Cap | 5.31B |
| Revenue (ttm) | 5.48M |
| Net Income (ttm) | -22.51M |
| EPS (ttm) | -2.17 |
| PE Ratio (ttm) | -28.89 |
| Forward PE | -147.52 |
| Analyst | Strong Buy |
| Ask | 65 |
| Volume | 769,198 |
| Avg. Volume (20D) | 1,434,753 |
| Open | 64.22 |
| Previous Close | 64.51 |
| Day's Range | 62.00 - 64.50 |
| 52-Week Range | 11.39 - 70.40 |
| Beta | 0.39 |
About VRNA
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the ...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 28, 2017
Employees 209
Stock Exchange NASDAQ
Ticker Symbol VRNA
Website https://www.veronapharma.com
Analyst Forecast
According to 6 analyst ratings, the average rating for VRNA stock is "Strong Buy." The 12-month stock price forecast is $72, which is an increase of 14.85% from the latest price.
Stock ForecastsNext Earnings Release
Verona Pharma is scheduled to release its earnings on May 8, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+5.67%
Verona Pharma shares are trading higher after the ...
Unlock content with
Pro Subscription
1 month ago
+5.68%
Verona Pharma shares are trading higher after Canaccord Genuity maintained a Buy rating on the stock and raised its price target from $44 to $72.
